A Landscape of Pharmacogenomic Interactions in Cancer

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation       | Iorio, F., T. Knijnenburg, D. Vis, G. Bignell, M. Menden, M. Schubert, N. Aben, et al. 2016. “A Landscape of Pharmacogenomic Interactions in Cancer.” Cell 166 (3): 740-754. doi:10.1016/j.cell.2016.06.017. http://dx.doi.org/10.1016/j.cell.2016.06.017. |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Published Version | doi:10.1016/j.cell.2016.06.017                                                                                                                                                                     |
| Citable link    | http://nrs.harvard.edu/urn-3:HUL.InstRepos:29002552                                                                                                                                               |
| Terms of Use    | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
A Landscape of Pharmacogenomic Interactions in Cancer

Graphical Abstract

Highlights

- We integrate heterogeneous molecular data of 11,289 tumors and 1,001 cell lines
- We measure the response of 1,001 cancer cell lines to 265 anti-cancer drugs
- We uncover numerous oncogenic aberrations that sensitize to an anti-cancer drug
- Our study forms a resource to identify therapeutic options for cancer sub-populations

Authors
Francesco Iorio, Theo A. Knijnenburg, Daniel J. Vis, ..., Julio Saez-Rodriguez, Ultan McDermott, Mathew J. Garnett

Correspondence
um1@sanger.ac.uk (U.M.), mg12@sanger.ac.uk (M.J.G.)

In Brief
A look at the pharmacogenomic landscape of 1,001 human cancer cell lines points to new treatment applications for hundreds of known anti-cancer drugs.

Accession Numbers
GSE68379
E-MTAB-3610
SUMMARY

Systematic studies of cancer genomes have provided unprecedented insights into the molecular nature of cancer. Using this information to guide the development and application of therapies in the clinic is challenging. Here, we report how cancer-driven alterations identified in 11,289 tumors from 29 tissues (integrating somatic mutations, copy number alterations, DNA methylation, and gene expression) can be mapped onto 1,001 molecularly annotated human cancer cell lines and correlated with sensitivity to 265 drugs. We find that cell lines faithfully recapitulate oncogenic alterations identified in tumors, find that many of these associate with drug sensitivity/resistance, and highlight the importance of tissue lineage in mediating drug response. Logic-based modeling uncovers combinations of alterations that sensitize to drugs, while machine learning demonstrates the relative importance of different data types in predicting drug response. Our analysis and datasets are rich resources to link genotypes with cellular phenotypes and to identify therapeutic options for selected cancer sub-populations.

INTRODUCTION

Cancers arise because of the acquisition of somatic alterations in their genomes that alter the function of key cancer genes (Stratton et al., 2009). A number of these alterations are implicated as determinants of treatment response in the clinic (Chapman et al., 2011; Mok et al., 2009; Shaw et al., 2013). Studies from The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) have generated comprehensive catalogs of the cancer genes involved in tumorigenesis across a broad range of cancer types (Lawrence et al., 2014; Tamborero et al., 2013b; Zack et al., 2013). The emerging landscape of oncogenic alterations in cancer points to a hierarchy of likely functional processes and pathways that may guide the future treatment of...
Multi-omics data from 11,289 Patients

**A** Cancer Functional Event (CFE) selection from the analysis of patient tumor data

- DNA methylation
- Whole exome sequence
- Copy number (SNP6.0)
- 472 high-confidence cancer driver genes (CGs)
- 425 chromosomal regions of recurrent focal amplification/deletion (RACSs)
- 379 informative CpG islands (iCpGs)

**B** Characterization of cancer cell lines

Multi-omics data from 1,001 Cell lines

**C** Clinically relevant CFEs in cancer cell lines

- Mutated CG
- Wild-Type CG
- Not selected CG

**D** Drug screening

265 Compounds

- Cytotoxic
- Targeted

212,774 Compound/Cell line dose-response curves

1 compound

**E** Analyses

1. Comparison of cell lines and primary tumors across cancer types

2. Identification of clinically relevant markers of drug response

3. Predictive ability assessment of individual CFE/data-type and their combinations

- PTEN mutant
- PTEN deleted

http://www.cancerrxgene.org
patients (Ciriello et al., 2013; Hanahan and Weinberg, 2000; Stratton et al., 2009).

Clinical trials are complex and expensive, and pre-clinical data that helps stratify patients can dramatically increase the likelihood of success during clinical development (Cook et al., 2014; Nelson et al., 2015). Thus, pre-clinical biological models that, as much as reasonably possible, capture both the molecular features of cancer and the diversity of therapeutic responses are a necessity. Human cancer cell lines are a facile experimental model and are widely used for drug development. Large-scale drug sensitivity screens in cancer cell lines have been used to identify clinically meaningful gene-drug interactions (Barretina et al., 2012; Basu et al., 2013; Garnett et al., 2012; Seashore-Ludlow et al., 2015). In the past, such screens have labored under the limitation of an imperfect understanding of the landscape of cancer driver genes, but it is now possible to view drug sensitivity in such models through the lens of clinically relevant oncogenic alterations.

Here, we analyzed somatic mutations, copy number alterations, and hypermethylation across a total of 11,289 tumor samples from 29 tumor types to define a clinically relevant catalog of recurrent mutated cancer genes, focal amplifications/deletions, and methylated gene promoters (Figure 1A; Tables S1A–S1D). These oncogenic alterations were investigated as possible predictors of differential drug sensitivity across 1,001 cancer cell lines (Figures 1B and 1C; Table S1E) screened with 265 anti-cancer compounds (Figures 1D and S1; Table S1F). We have carried out an exploration of these data to determine (1) the extent to which cancer cell lines recapitulate oncogenic alterations in primary tumors, (2) which oncogenic alterations associate with drug sensitivity, (3) whether logic combinations of multiple alterations better explain drug sensitivity, and (4) the relative contribution of different molecular data types, either individually or in combination, in predicting drug response (Figure 1E).

RESULTS

Oncogenic Alterations in Human Tumors

We built a comprehensive map of the oncogenic alterations in human tumors using data from TCGA, ICGC, and other studies (Figure 1A; Table S1O). The map consisted of (1) cancer genes (CGs) for which the mutation pattern in whole-exome sequencing (WES) data is consistent with positive selection, (2) focal recurrently aberrant copy number segments (RACSs) from SNP6 array profiles, and (3) hypermethylated informative 5′C-phosphate-G-3′ sites in gene promoters (iCpGs) from DNA methylation data, hereafter collectively referred to as “Cancer functional events” (CFEs). We identified CFEs by combining data across all tumors (pan-cancer), as well as for each cancer type (cancer specific) (Tables S2A, S2D, and S2H).

The WES dataset consisted of somatic variant calls from 48 studies of matched tumor-normal samples, comprising 6,815 samples and spanning 28 cancer types (Tables S1A–S1D). CGs were detected per cancer type by combining the outputs of three algorithms: MutSigCV, OncodriveFM, and Oncodrive-CLUST (Lawrence et al., 2013; Rubio-Perez et al., 2015; Tamborero et al., 2013a). This identified 461 unique pan-cancer genes (Table S2A). We further added nine genes identified as putative tumor suppressors (Wong et al., 2014). We mined the COSMIC database to identify likely driver mutations in 358 of the 470 CGs (Table S2B; Supplemental Experimental Procedures). Most tumors harbored only a few driver mutations (median n = 2, range 0–64), consistent with previous reports (Kandoth et al., 2013; Vogelstein et al., 2013).

RACSs were identified using ADMIRE for the analysis of 8,239 copy number arrays spanning 27 cancer types (van Dyk et al., 2013) (Table S1D; Supplemental Experimental Procedures). In total, 851 cancer-specific RACSs were gained (286 segments) or lost (565 segments), with a median of 19 RACSs per tumor type (Table S2D). The median number of genes within each RACS was 15 for amplified regions and one for deleted regions. The majority of known driver gene amplifications (e.g., EGRF, ERBB2, MET, and MYC) and homozygous deletions (e.g., CDKN2A, PTEN, and RB1) were captured, with 320 RACSs (38%) containing at least one known putative cancer driver gene, in addition to 531 RACSs (62%) without known driver genes. A smaller pan-cancer set (due to overlap in RACSs across cancer types) was constructed by pooling these results, comprising 425 RACSs (117 amplified and 308 deleted) (Tables S2E–S2F).

iCpGs were identified using DNA methylation array data for 6,166 tumor samples spanning 21 cancer types (Table S1D). We defined 378 iCpGs based on a multimodal distribution of their methylation signal in at least one cancer type (Tables S2H and S2I). This also established a discretization threshold used to define such regions as hyper-methylated in the cell lines (Table S2J; Supplemental Experimental Procedures).

In total, our multidimensional analysis of >11,000 patient tumor samples identified 1,699 cancer-specific CFEs, which were further merged into 1,273 unique pan-cancer CFEs (Figure S2A).

Oncogenic Alterations in Patient Tumors Are Conserved across Cell Lines

Next, we assessed the extent to which the mutational landscape of cancer cell lines captures that seen in primary tumors. We utilized a panel of 1,001 human cancer cell lines analyzed through WES (n = 1,001), copy number (n = 996), gene expression...
(n = 968), and DNA methylation (n = 957) (http://cancer.sanger.ac.uk/cell_lines) (Figure 1B) and which we reclassified according to the TCGA tissue labels (Figure 2A; Tables S1A and S1E). Molecular alterations identified in cell lines were filtered using the CFEs identified in the primary tumor samples, providing a set of clinically relevant CFEs for the cell lines (Figure 1C).

Of the 1,273 pan-cancer CFEs identified in patient tumors, 1,063 (84%) occurred in at least one cell line, and 1,002 (79%) occurred in at least three (Figure 2A). This concordance was greatest for the RACSs (100% of 425; Table S2G), followed by iCpGs (338 of 378, 89%; Table S2J) and CGs (300 of 470, 64%; Table S2C). When considering cancer-specific CFEs, concordance was highest for CFEs occurring in at least 5% of patients (median of 86% of CFEs covered across cancer types; Table S2C). When we include infrequent CFEs (occurring in < 5% of patients), this concordance is markedly lower for the majority of cancer types (median coverage = 46%; Figure S2B). CFEs absent in cell lines are reported in Table S2K.

The correlation between the frequency of CFEs in cell lines and patient tumors was high for the majority of the cancer types and for all three classes of CFEs (Figures 2B and S2C; Table S2L). Using a simple nearest-neighbor classifier based on the presence of CFEs in cell lines and tumors across cancer types, we could correctly match the tissue of origin of cell lines to primary tumors (and vice versa) for 71% of the cases (27 out of 38 alteration profiles [randomly expected 1%]) (Figures S2D and S2E; Table S2M; Supplemental Experimental Procedures). This percentage increased to 81% and 92% (randomly expected 2% and 5%), when considering the second and fifth nearest-neighbors, respectively (Figure S2E).

The frequency of alterations in 13 canonical cancer-associated pathways was highly correlated between cell lines and tumors of the same cancer type (median $R = 0.75$ across all 13 pathways) (Figure 3A; Table S3A).

A previous hierarchical classification of ~3,000 tumors identified two major subclasses: M and C class (dominated by mutations and copy number alterations, respectively) (Ciriello et al., 2013). We expanded this analysis by including methylation data and by jointly analyzing cell lines and tumor samples. This integrated analysis of 3,673 samples (composed of 1,001 cell lines and 2,672 primary tumors for which all three data types were available) and that were positive for at least one of the 1,250 CFEs (Tables S3B and S3C) yielded four classes referred to as M, H, CD, and CA (Table S3D; Supplemental Experimental Procedures). Class M is enriched for CG mutations, class H for hypermethylation of iCpGs, and classes CD and CA for deleted and amplified RACSs, respectively (Figures 3B and S3; Tables S3E, S3F, and S3H; Data S1B). We observed a high concordance between the predominant class of CFEs in primary tumors and cell lines of the same tissue type (80% of cancer types, exceptions being GBM, KIRC, and PRAD) (Figure 3C; Table S3G; Data S1B).

Taken together, these results show that a sufficiently large panel of cell lines is able to capture individual clinically relevant genomic alterations, in addition to pathway alterations and global signatures of driver events.

A Therapeutic Landscape of Human Cancers

Modeling Pharmacogenomic Interactions

To investigate how CFEs detected in primary tumors impact drug response, we first mapped these on our panel of cell lines (Figure 1C; Tables S2C, S2G, and S2J). Cell lines underwent extensive drug sensitivity profiling, screening 265 drugs across 990 cancer cell lines and generating 212,774 dose response curves (median number of screened cell lines per drug = 878, range = [366, 935]; Figure 1D). This is an expansion on previous pharmacogenomic datasets (Barretina et al., 2012; Basu et al., 2013; Garnett et al., 2012; Seashore-Ludlow et al., 2015). The effect of each drug on cell number was used to model sensitivity as IC50 (drug concentration that reduces viability by 50%) or AUC (area under the dose-response curve) values (Tables S4A and S4B).

Screened compounds included cytotoxics (n = 19) and targeted agents (n = 242) selected against 20 key pathways and cellular processes in cancer biology (Figure 1D; Table S1F). These 265 compounds include clinical drugs (n = 48), drugs currently in clinical development (n = 76), and experimental compounds (n = 141). We screened seven compounds as biological replicates and observed good correlation between replicate IC50 values with a median Pearson correlation ($R = 0.65$ (0.78 for the compounds with most of IC50 values falling within the range of tested concentrations) and consistent classification of cell lines as sensitive or resistant to a compound (median Fisher’s exact test [FET] log10 p value = −26) (Figure S1). Cluster analysis based on AUC values confirmed that compounds with overlapping nominal targets or targeting the same process/pathway had similar activity profiles (Table S1G; Supplemental Experimental Procedures).

We used three distinct analytical frameworks to define the contribution of CFEs to the prediction of drug sensitivity (Figure 1E). ANOVA was used to identify single CFEs as markers of drug response. Logic models identified combinations of CFEs that improve the prediction of drug response. Lastly, we used machine-learning algorithms to assess the contribution of
each molecular data type (CGs, RACS, iCpGs, and gene expression) in explaining variation in drug response. For consistency, all analyses used IC_{50} values. We carried out a pan-cancer, as well as a cancer-specific, analysis (for those 18 cancer types of sufficient sample size, n > 15 cell lines).

**ANOVA Analysis Defines a Landscape of Pharmacogenomic Interactions**

For pan-cancer ANOVA, the set of CFEs included 267 CGs, 407 RACSs, and three gene fusions (BCR-ABL, EWSR1-FLI1, and EWSR1-X). Overall, for the 265 compounds, we identified 688 statistically significant interactions between unique CFE-drug pairs (p value < 10^{-3} at a false discovery rate [FDR] < 25%; Figure 4A), with 540 pan-cancer and 174 cancer-specific hits (Figure S4A; Table S4C). A subset of 262 CFE-drug pairs was additionally defined as large-effect interactions (Figure 4A). The effect size was quantified through Glass deltas (D_s) and Cohen’s D (CD) (Supplemental Experimental Procedures).

The majority of CFE-drug interactions was exclusively identified in either the pan-cancer or cancer-specific analysis (n = 662 of 688 significant interactions, 96%, and n = 254 of 262 significant large-effect interactions, 97%), with few overlapping interactions (Figure 4A; Table S4C). The effect size was frequently greater for the cancer-specific associations than for pan-cancer associations (CD > 1 for 100% and 30% of hits, respectively).

**Figure 3. Comparative Analysis of Pathway Alterations and Global CFE Signatures in Cell Lines and Tumors**

(A) Concordance of CFEs in cancer-associated pathways between cell lines and tumors.

(B) Enrichments of the dominant CFE type across four global classes.

(C) Classification of primary tumors and cell lines from each cancer type into global classes based on CFEs. Segment lengths are the percentage of samples (cell lines or primary tumors) falling within each global class. For primary tumors, results are compared to published classifications (Ciriello et al., 2013) (top diagram), and for cell lines, the comparison is with primary tumors from the same cancer type (bottom diagram). The classification of concordance is based on the identity of the predominant class of CFEs.

See also Figure S3, Table S3, and Data S1.
Among the individual CFE-drug associations, we identified many well-described pharmacogenomics relationships (Figure 4B). These included clinically relevant associations between alterations in BRAF, ERBB2, EGFR, and the BCR-ABL fusion gene and sensitivity to clinically approved drugs in defined tumor types, as well as associations between KRAS, PDGFR, PIK3CA, PTEN, CDKN2A, NRAS, TP53, and FLT3 with drugs that target their respective protein products or pathways (Figure 4B; Table S4C). Moreover, we observed a secondary T790M EGFR mutation in lung adenocarcinoma (LUAD) and resistance to EGFR-targeted therapies (Gefitinib and Afatinib) (Godin-Heymann et al., 2010) (Table S4D; Supplemental Experimental Procedures). This highlights the utility of using a large cell line collection to increase statistical power and to preserve representation of diverse genotypes and histologies.

**ANOVA Identifies Known and Novel Gene-Drug Associations**

Among the individual CFE-drug associations, we identified many well-described pharmacogenomics relationships (Figure 4B). These included clinically relevant associations between alterations in BRAF, ERBB2, EGFR, and the BCR-ABL fusion gene and sensitivity to clinically approved drugs in defined tumor types, as well as associations between KRAS, PDGFR, PIK3CA, PTEN, CDKN2A, NRAS, TP53, and FLT3 with drugs that target their respective protein products or pathways (Figure 4B; Table S4C). Moreover, we observed a secondary T790M EGFR mutation in lung adenocarcinoma (LUAD) and resistance to EGFR-targeted therapies (Gefitinib and Afatinib) (Godin-Heymann et al., 2008) (Figure 4D), as well as resistance of NRAS mutated melanoma patients to a BRAF inhibitor (Figure 4B; Table S4C) (Su et al., 2012).

A pathway-centric view highlighted the number of interactions between CFEs in cancer pathways (EGFR, ERK-MAPK, PI3K-MTOR, and DNA repair and cell-cycle-related pathways) and drugs targeting those CFEs (Figure S4I). For example, compounds targeting EGFR signaling showed potent activity in cells with EGFR and ERBB2 alterations, but were ineffective in cells with downstream alterations in ERK-MAPK signaling, such as mutant RAS.

To explore the most important CFE-drug interactions, we focused on 262 associations with a large effect on drug sensitivity (p < 10^{-3}, FDR < 25%, and Δ > 1, for both the cell line populations included in the test) (Figure 4C; Table S4C). For example, at the pan-cancer level, U2AF1 mutations associate with sensitivity to multiple FLT3 inhibitors, such as AC220 (p = 8.3 × 10^{-8}, CD = 2.5), Sorafenib (p = 3.04 × 10^{-6}, CD = 2.8), Sunitinib (p = 5.6 × 10^{-5}, CD = 2.5), and XL-184 (p = 1.3 × 10^{-4}, CD = 1.9); PTEN mutations associate with sensitivity to an AKT inhibitor in COAD/READ (p = 3.5 × 10^{-6}, CD = 2.4). The chemotherapeutic Mitomycin C is widely used to treat BLCA, and here, we detect, in the BLCA specific analysis, a sensitizing interaction with mutations in TP53 (p = 9.9 × 10^{-5}, CD = 2.8) that are highly prevalent in this cancer type. In LUSC cells, loss-of-function mutations in the DNA methyltransferase MLL2 are associated with sensitivity to the clinical anti-androgen Bicalutamide (p = 6.02 × 10^{-4}, CD = 3); the BCL-2 inhibitor, ABT-263, shows activity in COAD/READ cells that harbor focal amplifications of MET (p = 1.02 × 10^{-4}, CD = 2.8) or FOXA1/CRNKL1 (p = 1.31 × 10^{-4}, CD = 2.2), events found in almost 60% of colorectal tumors; and truncating mutations in the co-repressor of BCL6, BCO, statistically interact (p = 2.04 × 10^{-5}, CD = 3.5) with sensitivity to a PKC beta inhibitor in STAD (Figure 4D), and deletions of a RACS (2q37.3) containing MTERFD2 and SNAI1 is associated with resistance to the HDAC inhibitor Vorinostat (p = 5.4 × 10^{-7}, CD = 4; Figure 4D) in OV cell lines.

Interestingly, 24 of the 262 associations are driven by RACs that do not contain known cancer genes (Table S4C and S2D). For these regions, the patterns of drug sensitivity may give clues as to the likely contained driver cancer gene(s).

**Logic Formulas of Drug Response Refine Pharmacogenomic Modeling**

Many genomic alterations occur together or in a mutually exclusive way that suggests a biological function (Babur et al., 2015). We hypothesized that combinations of CFEs could, in some contexts, improve our ability to explain variation in drug sensitivity. We employed a computational approach termed “logic optimization for binary input to continuous output” (LOBICO) to find the optimal logic model combining CFEs to explain the IC_{50} values for a drug, for example, “if RAS or RAF mutated, then sensitive to MEK inhibition” (Knijnenburg et al., 2016). LOBICO binarizes the IC_{50} values, labeling cell lines as sensitive or resistant, and uses these together with the continuous IC_{50} to find optimal models (Table S5C) (Supplemental Experimental Procedures). We employed 5-fold cross-validation (CV) to select the appropriate model complexity from a set of eight possible models, ranging from single CFE predictor models to complex multi-input models with up to four CFEs. We required solutions to have specificity greater than 80%. The input features included the CGs, RACs, gene fusions, and binarized pathway activity scores derived from the basal gene expression profiles of the cell lines (Figure S5A; Tables S5A, S5B, and S5D). The latter is based on 11 transcriptional signatures of pathway activation (Parikh et al., 2010) (Table S5B; Supplemental Experimental Procedures).
Figure 4. Pharmacogenomic Modeling of Drug Sensitivity

(A) Pan-cancer and cancer-specific ANOVA analyses for statistically significant interactions between differential drug sensitivity and CFEs. Cancer-specific interactions are divided into those identified in a single or multiple cancer-specific analyses.

(B) A summary of established pharmacogenomic interactions detected in this analysis including a subset of clinically approved markers. The total number of significant and significant large-effect interactions for each cancer type is provided. Testable interactions that were validated on the CTRP datasets are also indicated.
LOBICO was executed for each drug separately utilizing pan-cancer and cancer-specific molecular datasets. This led to the inference of 1,112 logic models (Table S5E).

In the pan-cancer dataset we found that for 69% (182 of 265) of the drugs, the IC50s were better explained than expected by chance (p < 0.05 and FDR < 5%). Across the cancer-specific datasets, on average, 24% of the drugs were explained by the inferred logic models (Figure 5A). We termed these logic models (182 from the pan-cancer dataset and 208 from the 18 cancer-specific datasets) “predictive models”. When considered together, the pan-cancer and cancer-specific LOBICO analyses identified predictive models for 208 out of 265 (78%) drugs. Importantly, for 85% of the 390 predictive models, a multi-input model achieved better performance than did the best single-predictor model (Figure 5B). Although the pan-cancer dataset produced the largest number of predictive models, the CV error was consistently higher than for cancer-specific datasets (Figure S5B). This is in agreement with the ANOVA analysis, where larger effect sizes were observed for the cancer-specific datasets. The response to drugs that target the p53 or ERK-MAPK pathway were especially well-predicted by LOBICO (Figure S5C).

We observed that CGs had the largest role in explaining drug response, followed by RACSs and the pathway activities derived from gene expression (Figure S5A; Supplemental Experimental Procedures). The small number of pathway signatures had a disproportionately large effect in the logic models, showing that basal pathway activation scores provide relevant information to predict drug response beyond the genomic CFEs (Costello et al., 2014) (Figure S5D).

LOBICO uncovered many known, as well as novel, associations (Table S5F). Figure 5C depicts a selection of particularly strong and consistent “and/or” combinations found for clinically approved drugs. For example, in the pan-cancer dataset, the “or” combination of KRAS or BRAF improved the precision and recall compared to single predictor models to explain cell line sensitivity to a number of MEK and RAF inhibitors (e.g., Trametinib in Figures 5C and 5D).

In general, the “or” combinations led to models with higher recall (Figure 5C, right quadrants) as compared with the single-predictor model. For example, HNSC cell lines that have an EGFR amplification or a SMAD4 mutation account for 45% (10 out of 22) of cell lines sensitive to the ERRB2/EGFR inhibitor Afatibinib, whereas considering only the EGFR amplified cell lines accounts for only 32% (7 out of 22) of the sensitive cell lines (Figure 5E). Conversely, “and” combinations led to models with higher precision (Figure 5C, left quadrants). For example, BRCA cell lines that lack a deletion of the FAT1/IRF2 locus and are TP53 mutant show increased sensitivity to the ERRB2/EGFR inhibitor Lapatinib. This is achieved at higher precision (57% instead of 45% for the single predictor model), but at a lower recall (80% instead of 100%) (Figure 5F). Collectively, LOBICO analysis highlights the importance of considering combinations of oncogenic alterations as biomarkers for drug response.

Validation of Pharmacogenomic Modeling Results on Independent Datasets

We sought to validate our pharmacogenomic models using independent drug sensitivity datasets from the Cancer Cell Line Encyclopedia (CCLE) (Barretina et al., 2012) and the Cancer Therapeutics Response Portal (CTRP; second version) (Seashore-Ludlow et al., 2015). This analysis was for necessity restricted to only those compounds and cell lines shared with our own study (hereafter referred to as GDSC). The shared set consisted of 466 cell lines and 76 compounds from the CTRP study (Tables S4I–S4K) and 389 cell lines and 15 compounds from the CCLE study (Tables S4E–S4G; Supplemental Experimental Procedures). Validation was performed using IC50 values from the GDSC and CCLE studies and AUC values from the CTRP study (where IC50 values were not reported).

We performed ANOVA on the overlapping set of cell lines/compounds. We validated 53% (19 of 36 on CTRP) and 86% (6 of 7 on CCLE) of the testable sensitivity associations identified in the GDSC, and 21% (6 of 29 on CTRP) and 0% (0 of 7 on CCLE) of testable resistance associations (p < 0.05, Fisher’s exact test CTRP; p = 8.1 × 10−9; CCLE: p = 0.01; Figures S4J and S4K; Tables S4H and S4L; Supplemental Experimental Procedures). A significant Pearson correlation of the CFE-drug interaction significance was observed between the GDSC datasets and the other two datasets (R = 0.86 for CTRP and R = 0.86 for CCLE; Figures S4J and S4K). Similarly, using LOBICO, we validated 44% (17 of 39) of testable models using the CTRP, including both single and multi-input models, and observed a significant Pearson correlation of the interaction significance between the two datasets (R = 0.96; Figures S5E and S5F; Supplemental Experimental Procedures). A complete summary of these comparisons is provided in Tables S4E–S4L and S5G, Data S1C, and Supplemental Experimental Procedures.

Contribution of Different Molecular Data Types in Predicting Drug Response

To investigate the power of different combinations of molecular data to predict drug response, we built linear and non-linear models of drug sensitivity (elastic net [EN] regression and Random Forests [Costello et al., 2014]). As input features, we used CGs, RACSs, iCpGs, and gene expression data.

Here, we refer to EN models using IC50 values (Table S4A), but very similar results were obtained with Random Forests (Figure S6F; Table S6A). We assessed the predictive power of
Figure 5. Logic Models of CFEs Explain Drug Sensitivity
(A) The number of predictive LOBICO models from the pan-cancer and cancer-specific analyses. The number of cell lines for each cancer type is given in brackets.

(B) Optimal model complexity for each of the predictive logic models.

(C) Strong AND/OR model combinations involving clinically approved drugs from the pan-cancer and cancer-specific analyses. Each arrow goes from the precision (x axis) and recall (y axis) of the single-predictor model to that of the logic combination. The arrow color reflects cancer type, and drug names and nominal targets (italics) are shown.

(D) Distribution of IC50 values of all cell lines (gray) in response to Trametinib with respect to the KRAS mutant single-predictor model (red line) and the KRAS OR BRAF mutant combination (blue line). The dashed line is the IC50 threshold used to classify cell lines as sensitive and resistant. The inset table shows the number of cell lines classified as sensitive or resistant for each model and the associated precision (pr.) and recall (re.).

(E) HNSC cell lines response to Afatinib with respect to EGFR amplification and the combination of EGFR amplification OR a SMAD4 mutation.

(F) BRCA cell lines response to Lapatinib with respect to lack of the FAT1/IRF2 deletion and the logical TPS3 mutant AND lack of the FAT1/IRF2 deletion combination.

See also Figure S5, Table S5, and Data S1.

Each model using the Pearson correlation coefficient (R) of observed versus predicted IC50 values. For each of the 265 compounds, we built pan-cancer and cancer-specific models (for 18 cancer types) and considered a model with a corresponding $R_{pan-cancer} \geq 0.21$ and $R_{cancer-specific} \geq 0.25$ as predictive (Figures S6G and S6H; Supplemental Experimental Procedures).

In a pan-cancer analysis, the most predictive data type was gene expression, closely followed by the tissue of origin of the cell lines (Figure 6A). By comparison, genomic features (CG mutations and RACSs alterations) performed poorly. The predictive power of gene expression and tissue type was strongly correlated, while RACSs and CGs are less correlated with the tissue type (Figure S6A). This is consistent with the tissue specificity of gene expression (Ross et al., 2000).

Next, we compared the most predictive data types in pan-cancer versus cancer-specific analyses (Figures 6B and 6C). For
each drug, we identified the best-performing combination of data types and the corresponding model, referred to as the “lead model”. Notably, paired molecular data types contributed to the most lead models in both the pan-cancer (~42% of all models) and the cancer-specific analyses (~45% for all cancer types) (Figures 4B and 4C). In the pan-cancer analysis, all of the lead models use gene expression data (Figures 6D and 6E), but for 211 drugs (~86%), the models are improved by including methylation, RACSs, CGs, or any combination of those additional data types. In addition, we identified 379 predictive (non-lead) models (~17%) independent of gene expression (Figures S6B–S6E).

In a cancer-specific analysis, the majority of lead models are based solely on genomics features (Figures 6D and 6E). For 120 cases (~38%) the lead model is based on genomics alone (CGs and RACS). We found that genomics in combination with methylation provided an additional 117 lead models (~37%), whereas genomics in combination with gene expression contributed 19 (~6%). The remaining lead models use methylation alone (~7%), gene expression alone (~3%), or a combination of genomic, epigenetic, and transcriptomic features (12%). Therefore, in the context of a cancer-specific analysis, ~74% (237 of 319) of lead models were explained by genomics, either alone or when combined with methylation (Figures 6D and 6E).

**DISCUSSION**

**Constructing a Pharmacogenomics Resource**

Cancer cell lines are important tools for drug development. Here, we have extended previous efforts with the systematic expansion of the pharmacological, genomic, transcriptomic, and epigenetic characterization of 1,001 human cancer cell lines. These datasets can be investigated through the COSMIC and Genomics of Drug Sensitivity in Cancer Web portal (http://www.cancerrxgene.org). To the best of our knowledge, this is the largest and most extensively characterized panel of cancer cell lines and should enable a broad range of studies linking genotypes with cellular phenotypes.

Our analysis of >11,000 patient tumor samples and the subsequent superimposing of salient cancer features on cell lines exemplifies how large-scale cancer sequencing can be used to empower biological research and maximizes the potential clinical relevance of the pharmacological models reported.

The majority of CFEs identified from a broad range of tumor types is captured within a large cell line panel and often at a frequency similar to that observed in patient cohorts. However, the picture is far from complete; many CFEs occurring at low to moderate frequency (2%–5%) are represented by a single cell line or not at all, and coverage by cancer type is variable. As
we enter an era of precision cancer medicine, where many drugs are active in small molecularly defined subgroups of patients (e.g., only 3%–7% of lung cancer patients harbor the drug sensitizing EML4-ALK gene fusion [Soda et al., 2007]), the scarcity of models for many cancer genotypes and tissues is a limitation. New cell culturing technologies enable derivation of patient cell lines with high efficiency and thus make derivation of a larger set of cell lines encompassing the molecular diversity of cancer a realistic possibility (Liu et al., 2012; Sato et al., 2011).

Pharmacogenomic Models of Drug Sensitivity
Pharmacogenomic screens in cancer cell lines are an unbiased discovery approach for putative markers of drug sensitivity. We identified a wealth of molecular markers of drug sensitivity, including completely novel associations not easily explained with our current knowledge. With appropriate validation and follow-up studies, these putative biomarkers may aid patient stratification and help to explain the heterogeneity of clinical responses.

Going beyond single gene-drug interactions, “logic” combinations of CFEs consistently perform better than single events in sensitivity prediction. Clinical support for this comes from the observation that BRAF mutant melanoma patients treated with BRAF inhibitors show heterogeneity of response that may be explained by the presence of additional molecular alterations (Chapman et al., 2011). Our analyses suggest that clinical studies in cancer patients should be designed to enable combinations of genomic alterations to be detected, which has implications for both trial size and the statistical approaches employed.

We validated our pharmacogenomic models using independent datasets from the CCLE and CTRP. Consistent with previous reports, this demonstrated good consistency in the set of markers identifiable across these studies (Cancer Cell Line Encyclopedia Consortium, 2015) and lends additional support to the results presented here. However, our ability to validate some pharmacogenomic associations was restricted by the limited number of overlapping cell lines and compounds between these studies. Furthermore, the consistency between datasets is not perfect, and efforts toward standardization to reduce methodological and biological differences across the different studies are likely to improve future correlation between datasets.

Glimpses of a Precision Medicine Landscape
For many of our pharmacological models, the defining CFE is present in clinical populations at a frequency that would make testing in a clinical trial setting feasible (Figure 7). For example, the alkylating agent Temozolamide (used to treat glioblastoma multiforme) shows activity in MYC amplified colorectal cancer lines (present in 33% of primary tumors) (Figure 7A). Overall, we found that a median of 50% of primary tumor samples harbor at least one CFE, or logic combination of CFEs, associated with increased drug response; ranging from 0.63% (OV) to 83.61% (COAD/READ) (Figure 7; Tables S7A–S7C; Supplemental Experimental Procedures). This suggests that there are likely to be a number of molecular subtypes within many cancers that, following appropriate validation, could be tested in the clinical trial setting using these stratifications for treatment selection.

Using machine learning, we determined that within each specific cancer type, genomic features (either driver mutations or copy number alterations) generated the most predictive models, with the addition of methylation data further improving our models. While informative in the pan-cancer setting, baseline gene expression data was less informative in the more clinically relevant tissue-specific setting. Prioritizing the design of diagnostics that deliver driver mutations, copy number alterations, and DNA methylation profiles might be the most cost effective means in the short-term to stratify patients for cancer treatment.

Conclusions
The clinical development of molecularly targeted cancer therapies remains a formidable challenge. Our current analysis is restricted by the availability of patient genomic datasets, the cell lines and compounds screened, and methodological and biological variables, as well as the inherent limitation associated with the use of in vitro cancer cell lines. Nonetheless, our results represent a comprehensive attempt to describe the landscape of clinically relevant pharmacogenomics interactions in cellular models of cancer, complementing previous efforts (Barretina et al., 2012; Basu et al., 2013; Garnett et al., 2012; Seashore-Ludlow et al., 2015). The data resource and analyses described here should enable the matching of drug response with oncogenic alterations to provide insights into cancer biology and to accelerate the development of patient stratification strategies for clinical trial design.

EXPERIMENTAL PROCEDURES

Cancer Cell Line Characterization
Genomic data for a panel of 1,025 genetically unique human cell lines were assembled from the COSMIC database. 1,001 cell lines were included in this study (Table S1B). Variants and copy number alterations were identified as described in the Supplemental Experimental Procedures. Microsatellite instability data were assembled as detailed in the Supplemental Experimental Procedures. Gene fusions from a subset cell lines (~700) were identified by targeted PCR sequencing or split probe fluorescence in situ hybridization (FISH) analysis (Table S2C).

Variant Identification in Tumors
Variant data from sequencing of 6,815 tumor normal sample pairs derived from 48 different sequencing studies were compiled (Rubio-Perez et al., 2015). To aid in the analysis, the tumor data were reannotated using a pipeline consistent with the COSMIC database (Vagrant: https://zenodo.org/record/16732#).
Methylation Data
For primary tumors, raw data for 6,035 methylation samples, covering 18 tumor types, were downloaded from the TCGA data portal. For the cell lines, data were generated in-house as described in the Supplemental Experimental Procedures. In both cases, Infinium HumanMethylation450 BeadChip arrays were preprocessed using the R Bioconductor package Minfi. Only CpG site probes falling on the promoter region of the known genes were considered, i.e., TSS1500, TSS200, 5' UTR, and 1st exon. Probes containing SNPs and non-specific probes, falling on sex chromosomes, and not associated with a gene were discarded. Methylation beta values of CpG islands were averaged across CpG sites.

Identification of Cancer Functional Events
The selection of cancer-driver genes (together with the variant recurrence filter) of the recurrently copy-number-altered chromosomal regions and the informative CpG islands is detailed in the Supplemental Experimental Procedures.

Gene Expression Data
Cell line pellets collected during exponential growth in RPMI or DMEM/F12 were lysed with TRizol (Life Technologies) and stored at −70°C. Following chloroform extraction, total RNA was isolated using the RNAeasy Mini Kit (QIAGEN). DNase digestion was followed by the RNAclean Kit (Agencourt Bioscience). RNA integrity was confirmed on a Bioanalyzer 2100 (Agilent Technologies) prior to labeling using 3′ IVT Express (Affymetrix). Microarray analysis was performed as described in the Supplemental Experimental Procedures.

Cell Line versus Tumor Comparisons
All analyses evaluating the extent to which cell lines resemble primary tumors are detailed in the Supplemental Experimental Procedures.

Cell Viability Assays
Experimental protocols used for compound screening are detailed in the Supplemental Experimental Procedures. Effects on cell viability were measured, and a curve-fitting algorithm was applied to this raw dataset to derive a multiparameter description of the drug response (half maximal inhibitory concentration [IC50]; area under the curve [AUC]) through a multilevel mixed model (Vis et al., 2016) (Supplemental Experimental Procedures).

Statistical Models of Drug Response
For each drug, an ANOVA model was fitted to correlate drug response with the status of Cancer Functional Events (CFEs), as described in Garnett et al. (2012), implemented in GDSCtools (http://gdsc.tools/readthedocs.io) and detailed in the Supplemental Experimental Procedures. The downsampling ANOVA simulation studies are detailed in the Supplemental Experimental Procedures. We applied the LOBICO (Krijnenburg et al., 2016) framework as detailed in the Supplemental Experimental Procedures. Machine learning models were computed as detailed in the Supplemental Experimental Procedures.

ACCESSION NUMBERS
The accession numbers for the sequencing/copy number, transcriptional, and methylation data reported in this paper are, respectively, EGA: EGAS00001000978, GEO: GSE68379, and ArrayExpress: E-MTAB-3610.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, six figures, and seven tables, and one data file and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2016.06.017.

AUTHOR CONTRIBUTIONS
Conceptualization, F.I., T.A.K., D.J.V., G.R.B., M.P.M., M.Sc., J.S.-R., U.M., and M.J.G.; Software, F.I., T.A.K., D.J.V., M.P.M., M.Sc., T.C., H.L., and E.V.D.; Validation, F.I., T.A.K., D.J.V., M.P.M., N.A., S.B., H.L., P.G., and M.J.G.; Formal Analysis, F.I., T.A.K., D.J.V., M.P.M., and M.Sc.; Investigation, G.R.B., S.B., P.G., T.M., and L.R.; Resources, D.J.V., G.R.B., M.Sc., E.G., S.B., H.L., P.G., E.V.D., H.C., H.d.S., H.H., T.M., S.M., L.R., X.D., R.K.E., Q.L., T.M., Z.S.L., T.M., T., N.L.-B., P.R.-M., M.E., D.A.H., C.H.B., U.M., and M.J.G.; Data Curation, F.I., D.J.V., G.R.B., M.Sc., E.G., H.L., P.G., H.C., H.d.S., H.H., S.M., S.S., M.So., D.T., N.L.B., P.R.-M., L.F.A.W., J.S.-R., U.M., and M.J.G.; Writing – Original Draft, F.I., T.A.K., D.J.V., G.R.B., M.P.M., U.M., and M.J.G.; Writing – Review & Editing, F.I., T.A.K., D.J.V., G.R.B., M.P.M., M.Sc., N.A., L.F.A.W., J.S.-R., U.M., and M.J.G.; Visualization, F.I., T.A.K., M.M., E.G.; Supervision, D.A.H., M.R.S., C.H.B., L.F.A.W., J.S.-R., U.M., and M.J.G.; Project Administration, F.I., U.M., and M.J.G.; Funding Acquisition, D.A.H., C.H.B., M.R.S., L.F.A.W., J.S.-R., U.M., and M.J.G.

ACKNOWLEDGMENTS
This work was funded by the Wellcome Trust (086375 and 102696). F.I. was supported by the European Bioinformatics Institute and Wellcome Trust Sanger Institute post-doctoral (ESP0D) program. T.A.K. was supported by the National Cancer Institute (U24CA143835) and the Netherlands Organisation for Scientific Research. D.T. was supported by the People Programme (Marie Curie Actions) of the 7th Framework Programme of the European Union (FP7/2007-2013; 603088) and the Agency of Competitiveness for Companies of the Government of Catalonia (acció). N.L.-B. was supported by La Fundació la Marató de TV3. M.E. was funded by the European Research Council (268862), the Ministerio de Ciencia e Innovacion (SAF2011-22803), the Institute of Health Carlos III (ISCIII) under the Integrated Project of Excellence (PIE13/00022), the Spanish Cancer Research Network (RD12/0036/0039), the Health and Science Departments of the Catalan Government Generalitat de Catalunya 2014-SGR 633, and the Cellex Foundation. U.M. was supported by a Cancer Research UK Clinician Scientist Fellowship. We thank Aiqing He for expression data and Ilya Shmulevich for assistance with the LOBICO framework. We thank P. Campbell, M. Ranzani, J. Brammeld, M. Petják, F. Behan, C. Alsinet Armengol, H. Francies, V. Grinkevich, and A. “Lila” Mupo for useful comments. P.R.-M., H.C., and H.d.S. are employees and shareholders of Bristol-Myers Squibb. Research in the M.J.G. lab is supported in part with funding from AstraZeneca.

Received: August 7, 2015
Revised: December 23, 2015
Accepted: June 3, 2016
Published: July 7, 2016

REFERENCES
Babur, Ö., Gönen, M., Aksoy, B.A., Schultz, N., Ciriello, G., Sander, C., and Demir, E. (2015). Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations. Genome Biol. 16, 45.
Barretina, J., Caponigro, G., Stransky, N.,Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehár, J., Kryukov, G.V., Sonkin, D., et al. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607.
Basu, A., Bodycombe, N.E.,Cheah, J.H., Price, E.V., Liu, K., Schaefer, G.I., Ebright, R.Y., Stewart, M.L., Ito, D., Wang, S., et al. (2013). An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 154, 1151–1161.
Cancer Cell Line Encyclopedia Consortium; Genomics of Drug Sensitivity in Cancer Consortium (2015). Pharmacogenomic agreement between two cancer cell line data sets. Nature 528, 84–87.
Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al.; BRIM-3 Study Group (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, six figures, and seven tables, and one data file and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2016.06.017.
Ciriello, G., Miller, M.L., Aksoy, B.A., Senbabaoglu, Y., Schultz, N., and Sander, C. (2013). Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45, 1127–1133.

Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., and Pangalos, M.N. (2014). Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat. Rev. Drug Discov. 13, 419–431.

Costello, J.C., Heiser, L.M., Georgii, E., Gönen, M., Menden, M.P., Wang, N.J., Bansal, M., Ammad-ud-din, M., Hintsanen, P., Khan, S.A., et al.; NCI DREAM Community (2014). A community effort to assess and improve drug sensitivity prediction algorithms. Nat. Biotechnol. 32, 1202–1212.

Garnett, M.J., Edelman, E.J., Heidorn, S.J., Greenman, C.D., Dastur, A., Lau, K.W., Greninger, P., Thompson, I.R., Luo, X., Soares, J., et al. (2012). Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570–575.

Godin-Heymann, N., Ulkus, L., Brannigan, B.W., McDermott, U., Lamb, J., Mares-Marchesi, S., Settleman, J., and Haber, D.A. (2008). The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol. Cancer Ther. 7, 874–879.

Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57–70.

Kandoth, C., McLellan, M.D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J.F., Wyczalkowski, M.A., et al. (2013). Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339.

Knijnenburg, T., Klu, G., Iorio, F., Garnett, M., McDermott, U., Shmulevich, I., and Wessels, L. (2016). Logic models to predict continuous outputs based on binary inputs with an application to personalized cancer therapy. bioRxiv, doi: http://dx.doi.org/10.1101/036970.

Lawrence, M.S., Stojanov, P., Polak, P., Kryukov, G.V., Cibulskis, K., Sivachenko, A., Carter, S.L., Stewart, C., Mermel, C.H., Roberts, S.A., et al. (2013). Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218.

Lawrence, M.S., Stojanov, P., Mermel, C.H., Robinson, J.T., Garraway, L.A., Golub, T.R., Meyerson, M., Gabriel, S.B., Lander, E.S., and Getz, G. (2014). Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495–501.

Liu, X., Ory, V., Chapman, S., Yuan, H., Albanez, C., Kallakury, B., Timofeeva, O.A., Nealon, C., Dakic, A., Simic, V., et al. (2012). ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am. J. Pathol. 180, 599–607.

Mok, T.S., Wu, Y.-l., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpawerawong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 227–235.

Rubio-Perez, C., Tamborero, D., Schroeder, M.P., Antolin, A.A., Deu-Pons, J., Perez-Llamas, C., Mestres, J., Gonzalez-Pereda, A., and Lopez-Bigas, N. (2015). In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 27, 382–396.

Sato, T., Stange, E.D., Ferrante, M., Vries, R.G.J., Van Es, J.H., Van den Brink, S., Van Houtd, W.J., Prunk, A., Van Gorp, J., Siersma, P.D., and Clevers, H. (2011). Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 141, 1762–1772.

Seashore-Ludlow, B., Rees, M.G., Cheah, H.J., Colok, M., Price, E.V., Coletti, M.E., Jones, V., Bodycombe, N.E., Soule, C.K., Gould, J., et al. (2015). Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov. 5, 1210–1223.

Shaw, A.T., Kim, D.-W., Nakagawa, K., Seto, T., Crino´ , L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B.J., Blackhall, F., et al. (2013). Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385–2394.

Soda, M., Choi, Y.L., Enomoto, M., Takeda, S., Yamashita, Y., Ishikawa, S., Fujisawa, S., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566.

Stratton, M.R., Campbell, P.J., and Futreal, P.A. (2009). The cancer genome. Nature 458, 719–724.

Su, F., Viros, A., Milagre, C., Trunzer, K., Bollag, G., Spleiss, O., Reis-Filho, J.S., Kong, X., Koya, R.C., Flaherty, K.T., et al. (2012). RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207–215.

Tamborero, D., Gonzalez-Pereda, A., and Lopez-Bigas, N. (2013a). Oncodrive-CLUST: exploiting the positional clustering of somatic mutations to identify cancer genes. Bioinformatics 29, 2238–2244.

Tamborero, D., Gonzalez-Pereda, A., Perez-Llamas, C., Deu-Pons, J., Kandoth, C., Reimand, J., Lawrence, M.S., Getz, G., Bader, G.D., Ding, L., and Lopez-Bigas, N. (2013b). Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci. Rep. 3, 2650.

van Dyk, E., Reinders, M.J.T., and Wessels, L.F.A. (2013). A scale-space method for detecting recurrent DNA copy number changes with analytical false discovery rate control. Nucleic Acids Res. 41, e100.

Vis, D.J., Bombardelli, L., Lightfoot, H., Iorio, F., Garnett, M.J., and Wessels, L.F.A. (2016). Multilevel models improve precision and speed of IC50 estimations. Pharmacogenomics 17, 691–700.

Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A., Jr., and Kinzler, K.W. (2013). Cancer genome landscapes. Science 339, 1546–1558.

Wong, C.C., Martincorena, I., Rust, A.G., Rashid, M., Alfandaris, C., Alexandrov, L.B., Tiffen, J.C., Koya, R.C., Flaherty, K.T., et al.; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium (2014). Inactivating CUX1 mutations promote tumorigenesis. Nat. Genet. 46, 33–38.

Zack, T.I., Schumacher, S.E., Carter, S.L., Cherniack, A.D., Saksena, G., Tabak, B., Lawrence, M.S., Zhang, C.-Z., Wala, J., Mermel, C.H., et al. (2013). Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134–1140.